MAPT and Alzheimer disease: Given the meanwhile well-defined cascade of amyloid-β and tau induced neuro-inflammatory effects in AD that are mediated via activated microglia, reactive astrocytes, and lymphocytes infiltrating the AD-diseased brain, anti-inflammatory treatment of AD patients seems appropriate and promising to deliver one of the first disease modifying therapies against AD.